Condition: Head and Neck Cancer · Malignant Melanoma · Colorectal Cancer · Sponsor: GeneMedicine Co., Ltd.
The purpose of this study is to measure safety, tolerability, and preliminary antitumor efficacy of GM103 administered alone and in combination with pembrolizumab in patients with locally advanced, unresectable, refractory and/or metastatic solid tumors (including but not limited to head and neck cancer, malignant melanoma, CRC, renal cell carcinoma, cervical cancer, and breast cancer). Study details include:
This description comes directly from the study's public registry record.
KyoungRyun Park · +82 2 6214 3247 · krpark@gene-medicine.com
YunJoo Lee · +82 2 6214 3266 · yjlee@gene-medicine.com
Always discuss trial participation with your own doctor first.
| National Cancer Center | Goyang-si, Gyeonggi-do, South Korea | Not Yet Recruiting |
| Korea University Anam Hospital | Seoul, South Korea | Not Yet Recruiting |
| Hanyang University Seoul Hospital | Seoul, South Korea | Not Yet Recruiting |
| Severance Hospital, Yonsei University Health System | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06265025